A Comprehensive Study of Floating Drug Delivery Systems: Current Trends and Future Prospects


Published: 2023-09-22

DOI: 10.56557/upjoz/2023/v44i213666

Page: 40-49

K. Venkata Gopaiah *

Narasaraopeta Institute of Pharmaceutical Sciences, Narasaraopeta, Palnadu, A.P.- 522 601, India.

J. N. Suresh Kumar

Narasaraopeta Institute of Pharmaceutical Sciences, Narasaraopeta, Palnadu, A.P.- 522 601, India.

M. Ramya Teja

Narasaraopeta Institute of Pharmaceutical Sciences, Narasaraopeta, Palnadu, A.P.- 522 601, India.

T. Lokesh

Narasaraopeta Institute of Pharmaceutical Sciences, Narasaraopeta, Palnadu, A.P.- 522 601, India.

D. Sai Sruthi

Narasaraopeta Institute of Pharmaceutical Sciences, Narasaraopeta, Palnadu, A.P.- 522 601, India.

M. Roja

Narasaraopeta Institute of Pharmaceutical Sciences, Narasaraopeta, Palnadu, A.P.- 522 601, India.

N. Rushitha

Narasaraopeta Institute of Pharmaceutical Sciences, Narasaraopeta, Palnadu, A.P.- 522 601, India.

SK. Vahedunnisa

Narasaraopeta Institute of Pharmaceutical Sciences, Narasaraopeta, Palnadu, A.P.- 522 601, India.

*Author to whom correspondence should be addressed.


In this review studies on FDDS are to collate the present written work with a particular study that states the principles & mechanism of floating of drugs to achieve bioavailability in gastric retention. This development of FDDS includes the physiological and formulation fluctuations that affect gastric retention, the process of designing single-unit to multiple-unit in floating systems, and the specification of formulation aspects included in that review study. This study reviews summates for laboratory techniques, and in animal studies in evaluating for performance and their functionating in floating systems. These systems are very helpful in resolving various faults that are triggered during the formulation development in the pharmaceutical dosage forms of FDDS.

Keywords: FDDS, single-unit, multiple-units

How to Cite

Gopaiah, K. V., Kumar , J. N. S., Teja , M. R., Lokesh , T., Sruthi , D. S., Roja , M., Rushitha , N., & Vahedunnisa , S. (2023). A Comprehensive Study of Floating Drug Delivery Systems: Current Trends and Future Prospects. UTTAR PRADESH JOURNAL OF ZOOLOGY, 44(21), 40–49. https://doi.org/10.56557/upjoz/2023/v44i213666


Download data is not yet available.


Hirtz J. The git absorption of drugs in man: A review of current concepts and methods of investigation. Br J Clin Pharmacol. 1985;19:77S–83S. [PMC free article] [PubMed] [Google Scholar]

Ponchel G, Irache JM. Specific and non-specific bioadhesive particulate system for oral delivery to the gastrointestinal tract. Adv Drug Del Rev. 1998;34:191–219.

DOI: 10.1016/S0169-409X (98)00040-4. [PubMed] [Cross Ref] [Google Scholar]

Lenaerts VM, Gurny R. Gastrointestinal Tract-Physiological variables affecting the performance of oral sustained release dosage forms. In: Lenaerts V, Gurny R, editors. Bioadhesive Drug Delivery System. Boca Raton, FL: CRC Press; 1990. [Google Scholar]

Deshpande AA, Shah NH, Rhodes CT, Malick W. Development of a novel controlled-release system for gastric retention. Pharm Res. 1997;14:815–819.

DOI: 10.1023/A:1012171010492. [PubMed] [Cross Ref] [Google Scholar]

Rednick AB, Tucker SJ. Sustained release bolus for animal husbandry. US patent 3 507 952; April 22, 1970.

Davis SS, Stockwell AF, Taylor MJ, et al. The effect of density on the gastric emptying of single and multiple unit dosage forms. Pharm Res. 1986;3:208–213.

DOI: 10.1023/A:1016334629169. [PubMed] [Cross Ref] [Google Scholar]

Urguhart J, Theeuwes F. Drug delivery system comprising a reservoir containing a plurality of tiny pills. US patent 4 434 153; February 28, 1994.

Mamajek RC, Moyer ES. Drug dispensing device and method. US Patent 4 207 890. June 17, 1980.

Fix JA, Cargill R, Engle K. Controlled gastric emptying. III. Gastric residence time of a non-disintegrating geometric shape in human volunteers. Pharm Res. 1993;10:1087–1089.

DOI: 10.1023/A:1018939512213. [PubMed] [Cross Ref] [Google Scholar]

Kedzierewicz F, Thouvenot P, Lemut J, Etienne A, Hoffman M, Maincent P. Evaluation of peroral silicone dosage forms in humans by gamma-scintigraphy. J Control Release. 1999;58:195–205.

DOI: 10.1016/S0168-3659(98)00154-0. [PubMed] [Cross Ref] [Google Scholar]

Groning R, Heun G. Oral dosage forms with controlled gastrointestinal transit. Drug Dev Ind Pharm. 1984;10:527–539. DOI: 10.3109/03639048409041405. [Cross Ref] [Google Scholar]

Groning R, Heun G. Dosage forms with controlled gastrointestinal passage—studies on the absorption of nitro furantion. Int J Pharm. 1989;56:111–116. DOI: 10.1016/0378-5173(89)90003-3. [Cross Ref] [Google Scholar]

Desai S. A Novel Floating Controlled Release Drug Delivery System Based on a Dried Gel Matrix Network. Jamaica, NY: St John's University; 1984. [Google Scholar]

Vantrappen GR, Peeters TL, Janssens J. The secretory component of inter-digestive migratory motor complex in man. Scand J Gastroenterol. 1979;14:663–667. [PubMed] [Google Scholar]

Wilson CG, Washington N. The stomach: its role in oral drug delivery. In: Rubinstein MH, editor. Physiological Pharmaceutical: Biological Barriers to Drug Absorption. Chichester, UK: Ellis Horwood. 1989;47–70. [Google Scholar]

Desai S, Bolton S. A floating controlled release drug delivery system: in vitro- in vivo evaluation. Pharm Res. 1993;10:1321–1325. DOI: 10.1023/A:1018921830385. [PubMed] [Cross Ref] [Google Scholar]

Singh BN, Kim KH. Floating drug delivery systems: An approach to oral controlled drug delivery via gastric retention. J Control Release. 2000;63:235–259.

DOI: 10.1016/S0168-3659(99)00204-7. [PubMed] [Cross Ref] [Google Scholar]

Timmermans J, Andre JM. Factors controlling the buoyancy and gastric retention capabilities of floating matrix capsules: new data for reconsidering the controversy. J Pharm Sci. 1994;83:18–24.

DOI: 10.1002/jps.2600830106. [PubMed] [Cross Ref] [Google Scholar]

Mojaverian P, Ferguson RK, Vlasses PH, et al. Estimation of the gastric residence time of the Heidelberg capsules in humans: Effect of varying food composition. Gastroenterology. 1985; 89:392–397. [PubMed] [Google Scholar]

Bechgaard H, Ladefoged K. Distribution of pellets in the gastrointestinal tract. The influence on transit time is exerted by the density or diameter of pellets. J Pharm Pharmacol. 1978;30:690–692. [PubMed] [Google Scholar]

Garg S, Sharma S.Gastroretentive drug delivery systems. Business Briefing: Pharmatech 2003 Web Site; 5th edition. May 2003. Available:http://www.touchbriefings.com/cdps/cditem.cfm?NID=17&CID=5

Accessed: October 6, 2005.

Timmerman J, Gansbeke VB, Moes AJ. Assessing by gamma scintigraphy the in vivo buoyancy of dosage forms having known size and floating force profiles as a function of time. Vol I. Paris, France: APGI. 1989;42–51. [Google Scholar]

Yang L, Fassihi R. Zero order release kinetics from self-correcting floatable configuration drug delivery system. J Pharm Sci. 1996;85:170–173. DOI: 10.1021/js950250r. [PubMed] [CrossRef] [Google Scholar]

Burns SJ, Attwood D, Barnwell SG. Assessment of a dissolution vessel designed for use with floating and erodible dosage forms. Int J Pharm. 1998;160:213–218. DOI: 10.1016/S0378-5173(97)00312-8. [Cross Ref] [Google Scholar]

Joseph NJ, Laxmi S, Jayakrishnan A. A floating type oral dosage form for piroxicam based on hollow microspheres: in vitro and in vivo evaluation in rabbits. J Control Release. 2002;79:71–79.

DOI: 10.1016/S0168-3659(01)00507-7. [PubMed] [CrossRef] [Google Scholar]

Sheth PR, Tossounian JL. Sustained release pharmaceutical capsules. US patent 4,126,672; November 21, 1978.

Soppimath KS, Kulkarni AR, Rudzinski WE, Aminabhavi TM. Microspheres a floating drug delivery system to increase the gastric residence of drugs. Drug Metab Rev. 2001;33:149–160.

DOI: 10.1081/DMR-100104401. [PubMed] [Cross Ref] [Google Scholar]

Ichikawa M, Watanabe S, Miyake Y. A new multiple unit oral floating dosage system. I: Preparation and in vitro evaluation of floating and sustained-release kinetics. J Pharm Sci. 1991;80:1062–1066.

DOI: 10.1002/jps.2600801113. [PubMed] [Cross Ref] [Google Scholar]

Ichikawa M, Watanabe S, Miyake Y. Granule remaining in the stomach. US patent 4 844 905; July 4, 1989.

Yang L, Esharghi J, Fassihi R. A new intra gastric delivery system for the treatment of Helicobacter pylori-associated gastric ulcers: in vitro evaluation. J Control Release. 1999;57:215–222.

DOI: 10.1016/S0168-3659(98)00066-2. [PubMed] [Cross Ref] [Google Scholar]

Ozdemir N, Ordu S, Ozkan Y. Studies of floating dosage forms of furosemide: in vitro and in vivo evaluation of bilayer tablet formulation. Drug Dev Ind Pharm. 2000;26:857–866.

DOI: 10.1081/DDC-100101309. [PubMed] [Cross Ref] [Google Scholar]

Choi BY, Park HJ, Hwang SJ, Park JB. Preparation of alginate beads for floating drug delivery: effects of CO2 gas-forming agents. Int J Pharm. 2002;239:81–91.

DOI: 10.1016/S0378-5173(02)00054-6. [PubMed] [Cross Ref] [Google Scholar]

Li S, Lin S, Daggy BP, Mirchandani HL, Chien TW. Effect of formulation variables on the floating properties of gastric floating drug delivery system. Drug Dev Ind Pharm. 2002;28:783–793.

DOI: 10.1081/DDC-120003000. [PubMed] [Cross Ref] [Google Scholar]

Li S, Lim S, Chien TW, Daggy BP, Mirchandani HL. Statistical optimization of the gastric floating system for oral controlled delivery of calcium. AAPS PharmSciTech. 2001;2:E1–E1.

DOI: 10.1208/pt020101. [PMC free article] [PubMed] [Cross Ref] [Google Scholar]

Penners G, Lustig K, Jorg PVG. Expandable pharmaceutical forms. US patent 5 651 985; July 29, 1997.

Fassihi R, Yang L. Controlled release drug delivery systems. US patent 5 783 212; July 21, 1998.

Talwar N, Sen H, Staniforth JN. Orally administered controlled drug delivery system providing temporal and spatial control. US patent 6 261 601; July 17, 2001.

Michaels AS, Bashwa JD, Zaffaroni A. Integrated device for administering the beneficial drug at a programmed rate. US patent 3 901 232; August 26, 1975.

Michaels AS. Drug delivery device with a self-actuated mechanism for retaining the device in the selected area. US patent 3 786 813; January 22, 1974.

Baumgartner S, Kristel J, Vreer F, Vodopivec P, Zorko B. Optimisation of floating matrix tablets and evaluation of their gastric residence time. Int J Pharm. 2000;195:125–135.

DOI: 10.1016/S0378-5173(99)00378-6. [PubMed] [CrossRef] [Google Scholar]

Moursy NM, Afifi NN, Ghorab DM, El-Saharty Y. Formulation and evaluation of sustained release floating capsules of Nicardipine hydrochloride. Pharmazie. 2003;58:38–43. [PubMed] [Google Scholar]

Atyabi F, Sharma HL, Mohammed HAH, Fell JT. In vivo evaluation of a novel gastro retentive formulation based on ion exchange resins. J Control Release. 1996;42:105–113.

DOI: 10.1016/0168-3659(96)01344-2. [Cross Ref] [Google Scholar]

Thanoo BC, Sunny MC, Jayakrishnan A. Oral sustained release drug delivery systems using polycarbonate microspheres capable of floating on the gastric fluids. J Pharm Pharmacol. 1993;45:21–24. [PubMed] [Google Scholar]

Nur AO, Zhang JS. Captopril floating and/or bioadhesive tablets: Design and release kinetics. Drug Dev Ind Pharm. 2000;26:965–969.

DOI: 10.1081/DDC-100101323. [PubMed] [Cross Ref] [Google Scholar]

Bulgarelli E, Forni F, Bernabei MT. Effect of matrix composition and process conditions on casein gelatin beads floating properties. Int J Pharm. 2000;198:157–165.

DOI: 10.1016/S0378-5173(00)00327-6. [PubMed] [Cross Ref] [Google Scholar]

Whitehead L, Collett JH, Fell JT. Amoxycillin is released from a floating dosage form based on alginates. Int J Pharm. 2000;210:45–49. DOI: 10.1016/S0378-5173(00)00567-6. [PubMed] [Cross Ref] [Google Scholar]

Streubel A, Siepmann J, Bodmeier R. Floating matrix tablets based on low-density foam powder: effect of formulation and processing parameters on drug release. Eur J Pharm Sci. 2003;18:37–45.

DOI: 10.1016/S0928-0987(02)00223-3. [PubMed] [Cross Ref] [Google Scholar]

Asmussen B, Cremer K, Hoffmann HR, Ludwig K, Roreger M. Expandable gastro retentive therapeutic system with controlled active substance release in the gastrointestinal tract. US patent 6 290 989; September 18, 2001.

El-Kamel AH, Sokar MS, Gamal SS, Naggar VF. Preparation and evaluation of ketoprofen floating oral drug delivery system. Int J Pharm. 2001;220:13– 21.

DOI: 10.1016/S0378-5173(01)00574-9. [PubMed] [Cross Ref] [Google Scholar]

Illum L; Ping H. gastro retentive controlled release microspheres for improved drug delivery. US patent 6 207 197; March 27, 2001.

Streubel A, Siepmann J, Bodmeier R. Floating microparticles based on low-density foam powder. Int J Pharm. 2002;241:279–292. DOI: 10.1016/S0378-5173(02)00241-7. [PubMed] [Cross Ref] [Google Scholar]

Sheth PR, Tossounian JL. Novel sustained release tablet formulations. 4 167 558; September 11, 1979.

Ushomaru K, Nakachimi K, Saito H. Pharmaceutical preparations and a method of manufacturing them. US patent 4 702 918; October 27, 1987.

Bolton S, Desai S. Floating sustained release therapeutic compositions. US patent 4 814 179; March 21, 1989.

Kawashima Y, Niwa T, Takeuchi H, Hino T, Ito Y. Preparation of multiple unit hollow microspheres (micro balloons) with acrylic resins containing tranilast and their drug release characteristics (in vivo) J Control Release. 1991;16:279–290. DOI: 10.1016/0168-3659(91)90004-W. [Cross Ref] [Google Scholar]

Dennis A, Timmins P, Lel K. Buoyant controlled release powder formulation. US patent 5 169 638; December 8, 1992.

Spickett RGW, Vidal JLF, Escoi JC. Antacid preparation having prolonged gastric residence. US patent 5,288,506. February 22, 1993.

Franz MR, Oth MP. Sustained release, bilayer buoyant dosage form. US patent 5 232 704; August 3, 1993.

Wu W, Zhou Q, Zhang HB, Ma GD, Fu CD. Studies on nimodipine sustained release tablets capable of floating on gastric fluids with prolonged gastric resident time. Yao Xue Xue Bao. 1997;32:786–790. [PubMed] [Google Scholar]

Wong PSL, Dong LC, Edgren DE, Theeuwes F. Prolonged release active agent dosage form adapted for gastric retention. US patent 6 120 803; September 19, 2000.

Mitra SB. Sustained release oral medicinal delivery device. US patent 4 451 260. May 29, 1984.

Harrigan BM. Drug delivery device for preventing contact of the undissolved drug with the stomach lining. US patent 4 055 178; October 25, 1977.

Erni W, Held K. The hydrodynamically balanced system: A novel principle of controlled drug release. Eur Neurol. 1987;27:215–275. DOI: 10.1159/000116171. [PubMed] [Cross Ref] [Google Scholar]

Sheth PR, Tossounian J. The hydrodynamically balanced systems (HBS): A novel drug delivery system for oral use. Drug Dev Ind Pharm. 1984;10:313–339. DOI: 10.3109/03639048409064653. [Cross Ref] [Google Scholar]

Degtiareva H, Bogdanov A, Kahtib Z, et al. The use of third-generation antacid preparations for the treatment of patients with nonulcerous dyspepsia and peptic ulcer complicated by reflux esophagus [in Chinese] Liakrs' ka sprava. 1994;5–6:119–122. [PubMed] [Google Scholar]

Fabregas JL, Claramunt J, Cucala J, Pous R, Siles A. In vitro testing of an antacid formulation with prolonged gastric residence time (Almagate float coat) Drug Dev Ind Pharm. 1994;20:1199–1212.

DOI: 10.3109/03639049409038361. [CrossRef] [Google Scholar]

Washington N, Washington C, Wilson CG, Davis SS. What is liquid Graviscon? A comparison of four international formulations. Int J Pharm. 1986;34:105–109. doi: 10.1016/0378-5173(86)90015-3. [Cross Ref] [Google Scholar]

Katayama H, Nishimura T, Ochi S, Tsuruta Y, Yamazaki Y. Sustained release liquid preparation using sodium alginate for eradication of Helicobacter pylori. Biol Pharm Bull. 1999;22:55–60. [PubMed] [Google Scholar]

Yuasa H, Takashima Y, Kanaya Y. Studies on the development of intragastric floating and sustained release preparation. 1. Application of calcium silicate as a floating carrier. Chem Pharm Bull (Tokyo). 1996;44:1361–1366. [Google Scholar]

Kohri N, Naasani I, Iseki K. Improving the oral bioavailability of sulphiride by a gastric retained form in rabbits. J Pharm Pharmacol. 1995;48:371–374. [PubMed] [Google Scholar]

Hilton AK, Deasy PB. In vitro and in vivo evaluation of an oral sustained release floating dosage form of amoxicillin trihydrate. Int J Pharm. 1992;86:79–88. DOI: 10.1016/0378-5173(92)90033-X. [Cross Ref] [Google Scholar]

Kawashima Y, Niwa T, Takeuchi H, Hino T, Itoh Y. Hollow microspheres for use as a floating controlled drug delivery system in the stomach. J Pharm Sci. 1992;81:135–140. DOI: 10.1002/jps.2600810207. [PubMed] [Cross Ref] [Google Scholar]

Mazer N, Abhisch E, Gfeller JC, et al. Intragastric behavior and absorption kinetics of anormal and floating modified release capsules of isisradipineder fasted and fed conditions. J Pharm Sci. 1988; 77:647–657.

DOI: 10.1002/jps.2600770802. [PubMed] [Cross Ref] [Google Scholar]

Hashim H, Li WPA. Improving the release characteristics of water-soluble drugs from hydrophilic sustained-release matrices b in situ gas generation. Int J Pharm. 1987; 35:201–209.

DOI: 10.1016/0378-5173(87)90131-1. [Cross Ref] [Google Scholar]

Chen GL, Hao WH. In vitro performance of floating sustained release capsules of verapamil. Drug Dev Ind Pharm. 1998; 24:1067–1072. [PubMed] [Google Scholar]

Ichikawa M, Watanabe S, Miyake Y. A new multiple-unit oral floating dosage system. II: In vivo evaluation of floating and sustained-release characteristics with para amino benzoic acid and iso isosorbide di nitrate as model drugs. J Pharm Sci. 1991;80:1153–1156.

DOI: 10.1002/jps.2600801212. [PubMed] [Cross Ref] [Google Scholar]

Cheuh HR, Zia H, Rhodes CT. Optimization of Sotalol floating and bioadhesive extended-release tablet formulation. Drug Dev Ind Pharm. 1995;21: 1725–1747. DOI: 10.3109/03639049509069261. [Cross Ref] [Google Scholar]

USP 28 NF 23. Rockville, MD: US Pharmacopeia. 2005;2413.

Pillay V, Fassihi R. Evaluation and comparison of dissolution data derived from different modified release dosage forms: an alternative method. J Control Release. 1998;55:45–55.

DOI: 10.1016/S0168-3659(98)00022-4. [PubMed] [Cross Ref] [Google Scholar]

Kawashima Y, Niwa T, Takeuchi H, Hino T, Ito Y. Hollow microspheres for use as floating controlled drug delivery system in the stomach. J Pharm Sci. 1992;81:135–140.

DOI: 10.1002/jps.2600810207. [PubMed] [Cross Ref] [Google Scholar]

Sakuma S, Sudo R, Suzuki N, Kikuchi H, Akashi M, Hayashi M. Mucoadhesion of polystyrene nanoparticles having surface hydrophilic polymeric chains in the gastrointestinal tract. Int J Pharm. 1999; 177:161–172.

DOI: 10.1016/S0378-5173(98)00346-9. [PubMed] [Cross Ref] [Google Scholar]

Babu VBM, Khar RK. In vitro and In vivo studies of sustained release floating dosage forms containing salbutamol sulfate. Pharmazie. 1990;45:268–270. [PubMed] [Google Scholar]

Chen J, Blevins WE, Park H, Park K. Gastric retention properties of super porous hydrogel composites. J Control Release. 2000;64:39–51. DOI: 10.1016/S0168-3659(99)00139-X. [PubMed] [Cross Ref] [Google Scholar]

Menon A, Ritschel WA, Sakr A. Development and evaluation of a monolithic floating dosage form for furosemide. J Pharm Sci. 1994;83:239–245. DOI: 10.1002/jps.2600830225. [PubMed] [Cross Ref] [Google Scholar]

Whitehead L, Fell JT, Collett JH, Sharma HL, Smith A. In vivo study demonstrating prolonged gastric retention. J Control Release. 1998;55:3–12.

DOI: 10.1016/S0168-3659(97)00266-6. [PubMed] [Cross Ref] [Google Scholar]

Oth M, Franz M, Timmermans J, Moes A. The bilayer floating capsule: A stomach-directed drug delivery system for misoprostol. Pharm Res. 1992;9:298–302. DOI: 10.1023/A:1015870314340. [PubMed] [Cross Ref] [Google Scholar]

Miyazaki S, Yamaguchi H, Yokouchi C, Takada M, Huo WM. Sustained release and intra gastric floating granules of indomethacin using chitosan in rabbits. Chem Pharm Bull (Tokyo). 1988;36:4033–4038. [PubMed] [Google Scholar]

Malcolm SL, Allen JG, Bird H, et al. Single dose pharmacokinetics of Madopar HBS in volunteers. Eur Neurol. 1987;27:28S–35S. DOI: 10.1159/000116172. [PubMed] [Cross Ref] [Google Scholar]

Rouge N, Allémann E, Gex-Fabry M, et al. Comparative pharmacokinetic study of a floating multiple unit capsule, a high-density multiple unit capsule, and an immediate release tablet containing 25 mg atenolol. Pharm Acta Helv. 1998;73:81–87.

DOI: 10.1016/S0031-6865(97)00050-2. [PubMed] [Cross Ref] [Google Scholar]

Crevoisier C, Hoevels B, Zurcher G, Prada M. Bioavailability of L-dopa after Madopar HBS administration in healthy volunteers. Eur Neurol. 1987;27:36S– 46S.

DOI: 10.1159/000116173. [PubMed] [Cross Ref] [Google Scholar]

Marion MH, Stochi F, Malcolm SL, Quinn NP, Jenner P, Marsden CD. Single dose studies of a slow release preparation of Levodopa and benserazide (Madopar HBS) in Parkinson's disease. Eur Neurol. 1987;27:54S–58S.

DOI: 10.1159/000116193. [PubMed] [Cross Ref] [Google Scholar]

Cook JD, Carriaga M, Kahn SG, Schalch W, Skikne BS. Gastric delivery system for ion supplementation. Lancet. 1990;335: 1136–1139. DOI: 10.1016/0140-6736(90)91135-W. [PubMed] [Cross Ref] [Google Scholar]

Blaser MJ. Hypothesis on the pathogenesis and natural history of Helicobacter pylori-induced inflammation. Gastroenterology. 1992;102:720–727. [PubMed] [Google Scholar]

Gibaly EI. Development and evaluation of novel floating chitosan microcapsules: Comparison with nnonfloatingchitosan microspheres. Int J Pharm. 2002;249:39–47.

DOI: 10.1016/S0378-5173(02)00396-4. [PubMed] [Cross Ref] [Google Scholar]

Sato Y, Kawashima Y. In vitro and in vivo evaluation of riboflavin-containing micro balloons for a floating controlled drug delivery system in healthy human volunteers. J Control Release. 2003;93: 39–47.

DOI: 10.1016/S0168-3659(03)00370-5. [PubMed] [Cross Ref] [Google Scholar]

Shimpi S, Chauhan B, Mahadik KR, Paradkar A. Preparation and evaluation of diltiazem hydrochloride-Gelucire 43/01 floating granules prepared by melt granulation. AAPS PharmSciTech. 2004;5:E43–E43.

DOI: 10.1208/pt050343. [PMC free article] [PubMed] [Cross Ref] [Google Scholar]

Dave BS, Amin AF, Patel MM. Gastro retentive drug delivery system of ranitidine hydrochloride: Formulation and in vitro evaluation. AAPS PharSciTech. 2004;5 :E34–E34. DOI: 10.1208/pt050234. [PMC free article] [PubMed] [Cross Ref] [Google Scholar]

Sriamornsak P, Thirawong N, Puttipipatkhachorn S. Morphology and buoyancy of oil-entrapped calcium pectinate gel beads. The AAPS Journal. 2004;6:E24–E24. DOI: 10.1208/aapsj060324. [PMC free article] [PubMed] [Cross Ref] [Google Scholar]

Reddy L, Murthy R. Floating dosage systems in drug delivery. Crit Rev Ther Drug Carrier Syst. 2002;19:553–585.

DOI: 10.1615/CritRevTherDrugCarrierSyst.v19.i6.20. [PubMed] [Cross Ref] [Google Scholar]

Chitnis V, Malshe VS, Lalla JK. Bioadhesive polymer synthesis, evaluation, and and application in controlled release tablets. Drug Dev Ind Pharm. 1991;17: 879–892. DOI: 10.3109/03639049109040824. [Cross Ref] [Google Scholar]